Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


arGEN-x receives €1.5 million for enhancement of therapeutic antibodies

In early May 2015, arGEN-X N.V. (ARGX) received a €1.5 million grant from the Flemish IWT (the government agency for Innovation by Science and Tec…


V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

15 November 2018, Ghent (Belgium) - V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceutic…

POPULAR TAGS

Fresh money for llama biotech

Written by IL on in the category news with the tags , .


Ablynx and Argen-X, two Ghent based biopharmaceutical companies, who develop drugs based on llama antibodies, easily obtained new capital from investors.

ArgenX, active in the field of cancer immunotherapy and autoimmune diseases, has attracted additional funds of 30 million euros, through the placement of 2,703 million new shares with major US investors.

Ablynx aims to collect 60 million euros from institutional investors by placing up to 5.5 million new shares (less than 10% of the outstanding shares). Today, Ablynx has more than 40 program in various therapeutic areas such as inflammation, haematology, immuno-oncology, oncology and respiratory disease.

The funds will be used to perform clinical trials with the new drug candidates.

Read more about: , .

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


arGEN-x receives €1.5 million for enhancement of therapeutic antibodies

In early May 2015, arGEN-X N.V. (ARGX) received a €1.5 million grant from the Flemish IWT (the government agency for Innovation by Science and Tec…


V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

15 November 2018, Ghent (Belgium) - V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceutic…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

V-Bio Ventures Flanders.bio Itera Life Science KU Leuven XpandInnovation Biowin GSK Turnstone Janssen UGent

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.